Needham analyst Mayank Tandon maintains EPAM Sys (NYSE:EPAM) with a Buy and raises the price target from $400 to $415.
FDA Lifts Partial Clinical Hold For bluebird bio’s Sickle Cell Disease Studies For Patients Under The Age of 18
bluebird bio, Inc. (NASDAQ:BLUE) today announced that the U.S. Food and Drug Administration (FDA) lifted its partial clinical hold for patients under the age of 18 in studies evaluating lovotibeglogene autotemcel
